Table 3.

Univariate and multivariate predictors of progression-free survival.

Variables	Univariate Cox analysis			Multivariate Cox analysis
	HR	95% CI	p value	HR	95% CI	p value
Sex (men/women)	1.718	0.795-3.714	0.169
Age (years) (<50/≥50)	0.851	0.482-1.499	0.576
ECOG PS (0 + 1/2)	2.819	0.993-8.003	0.052	0.276	0.095-0.800	0.018
HBV infection (positive/negative)	1.312	0.588-2.927	0.507
Cirrhosis (yes/no)	1.113	0.669-1.723	0.518
Child–Pugh class (A/B)	0.849	0.459-1.569	0.601
AFP (ng/mL)(<400/≥400)	0.812	0.457-1.441	0.476
Tumor size (cm) (<10/≥10)	0.797	0.456-1.394	0.427
Extrahepatic metastasis (yes/no)	1.176	0.623-1.876	0.685
PVTT (I+II/III)	0.741	0.517-1.564	0.522
Albumin level (g/L) (<35/≥35) TBIL (μmol/L) (<20/≥20) ALT (U/L) (<35/≥35) AST (U/L) (<40/≥40) Number of TACE (1/2+3)	0.880 1.290 0.805 1.350 0.829	0.501-1.547 0.726-2.291 0.460-1.408 0.608-2.801 0.467-1.470	0.657 0.385 0.447 0.495 0.521
Treatment (T+S+ICIs/T+S)	2.483	1.378-4.473	0.002	0.376	0.207-0.682	0.001

ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus; type I, tumor thrombi involving segmental branches of portal vein or above; type II, tumor thrombi involving right/left portal vein; type III, tumor thrombi involving the main portal vein; TBIL, total bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors.